Eicosapentaenoic Acid Ethyl Ester
Myocardial Infarction, Unstable Angina Pectoris, Sudden Cardiac Death, Stroke, Peripheral Artery Disease
Kobe UniversitySmall moleculePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 95/ 100
Competitive context
16 Active assets in the Myocardial Infarction, Unstable Angina Pectoris, Sudden Cardiac Death, Stroke, Peripheral Artery Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
UMBELLATINE China National Center for Cardiovascular Diseases | Phase 4 | BB |
Tirzepatide Brigham and Women's Hospital | Phase 4 | BB |
Orforglipron Eli Lilly and Company | Phase 3 | B |
Retatrutide Eli Lilly and Company | Phase 3 | B |
Inclisiran Novartis Pharmaceuticals | Phase 3 | B |
View all 17 →
Same molecule, other indications
Eicosapentaenoic Acid Ethyl Ester is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →